期刊文献+

肿瘤相关巨噬细胞来源外泌体激活IFN通路促进胃癌细胞免疫逃逸 被引量:8

Tumor-associated macrophages-derived exosomes promote immune escape of gastric cancer cells via IFN pathway
原文传递
导出
摘要 为探讨肿瘤相关巨噬细胞(tumor associated macrophage,TAM)外泌体促进胃癌细胞发生免疫逃逸的机制,采用体外诱导M2型巨噬细胞的方法模拟TAM,通过超速离心法提取M2型巨噬细胞外泌体(M2 macrophages’exosome,M2e),并与胃癌细胞共培养以获得摄取了M2e的胃癌细胞,再与CD8^(+)T细胞进行共培养。使用天冬氨酸半胱氨酸特异性蛋白酶(cysteinyl aspartate specific proteinase,Caspase)-3/7的荧光底物和AnnexinV-7-氨基放线菌素D(7-amino-actinomycin D,7-AAD)试剂检测胃癌细胞的凋亡情况,以评估T细胞的杀伤作用。利用MicroArray技术深入探索M2e影响胃癌细胞的信号通路,并用RT-PCR、Western blotting和流式细胞术对这一信号通路进行进一步的验证。结果显示,胃癌细胞能大量摄取M2e。相比未摄取M2e的胃癌细胞,摄取了M2e的胃癌细胞与活化T细胞共培养后,凋亡比例下降,说明其能减弱CD8^(+)T细胞的杀伤作用。MicroArray结果显示,摄取了M2e的胃癌细胞IFN通路被广泛激活。IFN通路激活能促进胃癌细胞表达PD-L1,进而使活化的CD8+T细胞的杀伤功能减弱,因此胃癌细胞产生了免疫逃逸。该研究揭示,巨噬细胞与胃癌细胞的信息交互作用使胃癌细胞产生了抗免疫杀伤作用,胃癌细胞免疫逃逸可能与TAM外泌体有潜在联系。 To explore the mechanism of immune escape of gastric cancer cells promoted by tumor-associated macrophage(TAM)-derived exosomes,M2 macrophages were induced in vitro and M2 macrophages’exosomes(M2 e)were extracted by ultracentrifugation.The M2 e thus produced were co-cultured with gastric cancer cells,and those that having taken M2 e(M2 e-containing gastric cancer cells)were further co-cultured with CD8^(+)T cells.The killing effect of CD8^(+)T cells was evaluated by detection of apoptotic gastric cancer cells by fluorescent substrate of cysteinyl aspartate specific proteinase(Caspase)-3/7 and AnnexinV-7-amino-actinomycin D(7-AAD)reagent.MicroArray technology was used to further explore the signal pathway that may be involved.Finally,RT-PCR,Western blotting and flow cytometry were used to verify the signaling pathway involved.The results showed that gastric cancer cells could uptake a large amount of M2 e.Compared with the original gastric cancer cells,the apoptosis rate of M2 e-uptaking gastric cancer cells decreased after co-culture with activated T cells.This indicated that the exosome could weaken the killing effect of CD8~+T cells.MicroArray results showed that IFN signaling was activated in M2 e-containing gastric cancer cells.The activation of IFN pathway could promote the expression of PD-L1 on gastric cancer cells,which impaired the killing function of activated CD8~+T cells in turn,leading to the immune escape of gastric cancer cells.This study revealed the anti-immune killing effect of gastric cancer cells caused by the exosomes interaction between M2 macrophages and gastric cancer cells,suggesting a connection between gastric cancer immune escape and TAM exosomes.
作者 郑乃盛 汪婷婷 袁向亮 沈立松 ZHENG Nai-sheng;WANG Ting-ting;YUAN Xiang-liang;SHEN Li-song(Department of Clinical Laboratory,Shanghai Xinhua Hospial,Shanghai Jiao Tong University School of Medicine,Shanghai 200082,China)
出处 《现代免疫学》 CAS 北大核心 2021年第1期24-31,共8页 Current Immunology
基金 国家自然科学基金(81772525)。
关键词 肿瘤相关巨噬细胞 外泌体 干扰素通路 肿瘤免疫逃逸 tumor associated macrophage exosome interferon signaling pathway tumor immune escape
  • 相关文献

参考文献1

二级参考文献22

  • 1Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC,McDermott DF, Powderly JD, Carvajal RD, Sosman JA, AtkinsMB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG,Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM,McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S,McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety,activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med 2012; 366: 2443-2454 [PMID: 22658127 DOI:10.1056/NEJMoa1200690].
  • 2Dunn GP, Old LJ, Schreiber RD. The three Es of cancerimmunoediting. Annu Rev Immunol 2004; 22: 329-360 [PMID:15032581 DOI: 10.1146/annurev.immunol.22.012703.104803].
  • 3Badoual C, Combe P, Gey A, Granier C, Roussel H, De GuillebonE, Oudard S, Tartour E. [PD-1 and PDL-1 expression in cancer:significance and prognostic value]. Med Sci (Paris) 2013; 29:570-572 [PMID: 23859507 DOI: 10.1051/medsci/2013296005].
  • 4Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and itsligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704 [PMID: 18173375 DOI: 10.1146/annurev.immunol.26.021607.090331].
  • 5Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA,Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC,Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM,Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, QuirtI, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM,Hoos A, Urba WJ. Improved survival with ipilimumab in patientswith metastatic melanoma. N Engl J Med 2010; 363: 711-723[PMID: 20525992 DOI: 10.1056/NEJMoa1003466].
  • 6Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C,Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, RichardsJ, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M,Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R,Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previouslyuntreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526 [PMID: 21639810 DOI: 10.1056/NEJMoa1104621].
  • 7Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, HwuP, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, HamidO, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S,Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, PardollDM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-2465 [PMID: 22658128 DOI: 10.1056/NEJMoa1200694].
  • 8Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, BellmuntJ, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS,Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatmentleads to clinical activity in metastatic bladder cancer. Nature 2014;515: 558-562 [PMID: 25428503 DOI: 10.1038/nature13904].
  • 9Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB,Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L.Tumor-associated B7-H1 promotes T-cell apoptosis: a potentialmechanism of immune evasion. Nat Med 2002; 8: 793-800 [PMID:12091876 DOI: 10.1038/nm730].
  • 10Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X,Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M,Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, LugliA, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC, TornilloL. Clinical impact of programmed cell death ligand 1 expressionin colorectal cancer. Eur J Cancer 2013; 49: 2233-2242 [PMID:23478000 DOI: 10.1016/j.ejca.2013.02.015].

共引文献11

同被引文献64

引证文献8

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部